Semaglutide vs AOD-9604

What Are Semaglutide and AOD-9604?

Semaglutide (Semaglutide (GLP-1 receptor agonist)) is a GLP-1 receptor agonist incretin mimetic. Synthetic GLP-1 analog developed by Novo Nordisk with amino acid modifications for extended half-life. It is researched for weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression.

AOD-9604 (Fragment 177-191 of Human Growth Hormone (modified)) is a Lipolytic peptide, GH fragment analog. Synthetic analog of human GH fragment 177-191, engineered to selectively activate lipolysis without systemic GH effects. It is researched for fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.

While both are popular research peptides, they work through fundamentally different mechanisms and serve different primary purposes.

How Do Semaglutide and AOD-9604 Work Differently?

Semaglutide mechanism: Activates GLP-1 receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion and inhibit glucagon release. Crosses the blood-brain barrier to activate hypothalamic GLP-1 receptors, reducing hunger signaling, increasing satiety, and modulating energy expenditure through CNS appetite pathways.

AOD-9604 mechanism: Activates beta-3 adrenergic receptors in adipose tissue, triggering cAMP-mediated lipolysis and release of stored fat for energy. Suppresses lipogenesis (new fat formation) while promoting fat breakdown. Unlike full growth hormone, it does not raise IGF-1 or impact glucose metabolism, blood sugar, or insulin sensitivity.

These distinct mechanisms are why the two peptides are often used for different research goals — or combined to target multiple pathways.

How Do the Dosing Protocols Compare?

Semaglutide: 0.25-2.4 mg weekly (injection) or 3-14 mg daily (oral) administered once weekly (injection) or daily (oral) via subcutaneous injection or oral. Half-life: 7 days. Cycle: ongoing, titrated over 4-5 weeks.

AOD-9604: 250-1000 mcg daily administered once daily, ideally morning fasted via subcutaneous injection. Half-life: not established. Cycle: 12-24 weeks.

Use our peptide calculator for reconstitution math for either compound.

How Do the Benefits Compare?

Semaglutide benefits: weight loss (16-22.5%), glycemic control, cardiovascular event reduction, appetite suppression.

AOD-9604 benefits: fat loss, increased fat oxidation, improved body composition, joint health support, no IGF-1 elevation.

The overlap in benefits determines whether these peptides compete for the same use case or complement each other in a stack.

How Do the Side Effects Compare?

Semaglutide: Nausea, vomiting, diarrhea (20-40% incidence, decreasing over 4-8 weeks). Thyroid C-cell tumor risk in rodents (human relevance unclear). Rare pancreatitis and diabetic retinopathy worsening.

AOD-9604: Well-tolerated across 900+ participants in clinical trials. Minimal adverse effects — potential mild headache, dizziness, or injection site reactions. One of the safest peptides in terms of documented human tolerability.

Can You Stack Semaglutide and AOD-9604 Together?

Many researchers combine Semaglutide and AOD-9604 in stacking protocols. The different mechanisms mean they can potentially provide complementary effects without competing for the same receptors.

Dual pathway activation possible with GIP agonists (tirzepatide). Complements SGLT2 inhibitors for enhanced glycemic control. See our stacking guide for general principles.

Which Is Better: Semaglutide or AOD-9604?

There is no universal answer. Semaglutide may be preferable for researchers focused on weight loss (16-22.5%), while AOD-9604 is stronger for fat loss.

For the most comprehensive results, many researchers combine both. Review each compound's individual guide for detailed protocols: Semaglutide | AOD-9604.

Frequently Asked Questions